C the Signs
C the Signs is a London-based AI company that provides a clinical decision support platform for early cancer detection in primary care, integrated into NHS GP electronic medical record systems and deployed across 1,500+ UK practices covering 10M+ patient lives.
- Company typePrivate
- Founded2017
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What C the Signs does
C the Signs is a London-based, privately-held clinical AI company founded in 2017 by NHS doctors Dr. Bea Bakshi (CEO) and Dr. Miles Payling (CSO) to address late cancer detection in primary care. The company's core product is a clinical decision support platform that analyzes patient symptoms, risk factors, demographics, and electronic medical record data against more than 1,000 validated evidence-based data points to identify individuals at risk of cancer across 100+ cancer types in under 60 seconds. The platform is UKCA-marked, MHRA-regulated, and accredited under NHS Clinical Safety standards DCB0129/0160, and integrates natively into the three principal UK GP electronic medical record systems: EMIS Web (used by ~70% of English GP practices), SystmOne, and Vision. A complementary patient-facing product, the C my Signs Self-Assessment Service, enables direct self-referral pathways without a GP visit, with endometrial cancer live since August 2024 and colorectal and lung cancer pathways planned.
The company's technology is clinically validated across more than 500,000 patient records, achieving 99% sensitivity for cancer detection and 94% accuracy in predicting tumor site of origin, and is deployed in 1,500+ UK GP practices covering more than 10 million patient lives. To date, 70,000+ patients with cancer have been detected through the platform, with a cancer detection rate of 66% reported across deployments, up from 58.7% baseline. C the Signs is commissioned primarily through NHS Integrated Care Boards, Primary Care Networks, Cancer Alliances, and NHS England programmes, with services provided free of charge to individual clinicians. Strategic partnerships with Health Innovation East, Health Innovation Wessex, Somerset NHS Foundation Trust, East Midlands Cancer Alliance, and the Mayo Clinic (for research validation) anchor the go-to-market. The company has raised a £5 million seed round in February 2022 and an $8 million Series A led by Khosla Ventures in January 2025, primarily to fund expansion from the UK into the United States.
C the Signs firmographics
Firmographics- Name
- C the Signs
- Legal name
- C the Signs Limited
- Website
- https://cthesigns.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- C the Signs is a London-based AI company that provides a clinical decision support platform for early cancer detection in primary care, integrated into NHS GP electronic medical record systems and deployed across 1,500+ UK practices covering 10M+ patient lives.
- Ownership category
- akta.pro rank
C the Signs industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Computer Systems Design Services (541512)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)
- akta.pro secondary industry
- Patient Intake, Digital Registration & eForms (HLACAEAF)
Keywords
Where C the Signs is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
C the Signs business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- NHS Commissioning Contracts: C the Signs is commissioned by NHS-funded bodies including GP practices, Primary Care Networks, Integrated Care Boards, Cancer Alliances, and NHS England. Services are provided free to individual healthcare practitioners while payment comes from NHS commissioning bodies.
- Health Innovation Partnerships: Partnerships with Health Innovation East and Health Innovation Wessex support regional expansion and commissioning of the platform across NHS Integrated Care Systems.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Annual | Free for individual healthcare practitioners |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
C the Signs product offering
Product offeringCore offering
C the Signs is an AI-powered clinical decision support platform that analyzes patient symptoms, demographics, risk factors, and electronic medical record data across 1,000+ validated evidence-based data points to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with NHS GP systems (EMIS, SystmOne, Vision) and is complemented by a patient-facing self-assessment service enabling direct triage into diagnostic pathways.
Product overview
C the Signs offers an AI-powered clinical platform for early cancer detection, consisting of two integrated products: (1) The C the Signs Clinical Decision Support Platform — a core clinical decision support system used by GPs that analyzes patient symptoms, demographics, risk factors, and electronic medical records to identify cancer risk across 100+ cancer types in under 60 seconds, integrating directly with EMIS Web, SystmOne, and Vision GP systems; and (2) The C my Signs Self-Assessment Service — a patient-facing self-referral pathway that enables individuals to complete AI-driven symptom assessments directly (without GP referral), currently deployed for endometrial cancer with plans for colorectal and lung cancer pathways. Both products share the same underlying AI algorithms and evidence base, with the Self-Assessment Service representing an extension of the platform to direct patient use.
Differentiator
Problem solved
Functional benefit
Products and services
- C the Signs Clinical Decision Support Platform AI-powered clinical decision support system for GPs and primary care clinicians that analyzes patient symptoms, demographics, risk factors, and electronic medical records to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with EMIS Web, SystmOne, and Vision EMR systems and is used across over 1,500 UK GP practices covering 10+ million patient lives.
- C my Signs Self-Assessment Service Patient-facing AI-driven self-assessment and self-referral pathway that enables individuals to complete an evidence-based cancer risk assessment via the NHS App or website without a GP referral. Currently deployed for endometrial cancer, with patients triaged directly to ultrasound or diagnostic services if cancer risk is indicated.
Quantifiable outcome
- 66% cancer detection rate (up from 58.7%), representing a 12% relative increase in detection
- +7 more outcomes
Companies that use C the Signs
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
C the Signs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature5 records
C the Signs partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, flagship and minor.
- Health Innovation EastcoreHealth Innovation East commissioned the evaluation of C the Signs across Suffolk and North East Essex ICB, demonstrating 808% ROI. Subsequently supported expansion across Norfolk and Waveney ICB and broader East of England.
- East Midlands Cancer AlliancecorePartnership with East Midlands Cancer Alliance to deploy C the Signs across every GP practice in Northamptonshire, supporting equitable early cancer diagnosis across the county.
- Somerset NHS Foundation TrustflagshipPioneering partnership to launch UK's first AI-driven self-referral service for endometrial cancer, enabling women to self-refer for diagnostic ultrasound without GP referral. This model is being expanded to colorectal and lung cancer pathways.
- The Eve AppealminorWomen's cancer charity Ask Eve Nurse Service endorsed the endometrial cancer self-referral service, providing credibility and support for patient awareness.
- NHS England InHIP ProgrammecoreC the Signs deployment through NHS England's Innovation for Healthcare Inequalities Programme (InHIP) designed to reduce variation in access to care and improve outcomes across deprived communities.
- Health Innovation WessexcorePartnered with Health Innovation Wessex to launch C the Signs across 70 GP practices in Dorset ICS, supporting earlier cancer detection for a population with high cancer rates.
- Mayo CliniccoreResearch collaboration using Mayo Clinic patient data to validate C the Signs AI models. Multiple peer-reviewed studies published on early detection of lung, breast, prostate, colorectal, and pancreatic cancers.
- EMIScoreDeep integration with EMIS Web electronic medical record system, used by approximately 70% of GP practices in England, enabling seamless access to C the Signs cancer risk assessment within existing clinical workflows.
- SystmOne (TPP)coreIntegration with SystmOne electronic medical record system supporting thousands of GP practices, community services, and hospitals across the NHS.
Scale indicators13 records
Recent moves7 records
Expansion highlights5 records
C the Signs competitors and assessment
Company assessmentDirect peers
- CancerIQ: US-based cancer risk assessment and clinical decision support platform for primary care and OB/GYN practices. Most directly comparable to C the Signs: AI-driven hereditary and familial cancer risk prediction integrated into EHR workflow to support earlier identification and referral.
- Skin Analytics: UK-based AI medical device for skin cancer detection in primary care pathways, deployed through NHS commissioning. Comparable as a UK AI cancer detection CDS validated as a regulated medical device and integrated into NHS GP workflows.
- Kheiron Medical Technologies: UK-based AI company focused on breast cancer screening (Mia) deployed in NHS and European radiology pathways. Comparable as a UK-headquartered AI cancer detection company operating under MHRA regulations and selling into NHS commissioning structures.
- Cyted: UK-based AI-enabled diagnostic company focused on early cancer detection (esophageal and other GI cancers) through NHS pathways. Comparable as a UK AI cancer detection company building evidence and NHS commissioning traction in early-diagnosis pathways.
- Volpara Health: AI-driven breast cancer risk assessment and imaging analytics platform used in primary care and screening settings. Comparable as an AI clinical decision support and risk stratification tool for cancer in women's health pathways.
Emerging players
- Lunit: South Korea-based AI company providing cancer detection AI for radiology (mammography, chest x-ray) and pathology. Comparable as a regulated AI cancer detection CDS company expanding globally across healthcare systems.
- PathAI: US AI pathology company applying machine learning to cancer diagnostics and biomarker discovery. Comparable as an AI company building regulatory-grade cancer detection tools for clinical decision-making, though focused downstream on pathology rather than primary care.
Broad incumbents
- Tempus: US precision medicine company applying AI to clinical and molecular data for oncology decision support. Comparable in the use of AI to inform oncology clinical decision-making, though broader in scope (molecular profiling, trials) than C the Signs' primary care focus.
- Merative (formerly IBM Watson Health): Health technology incumbent offering oncology-focused clinical decision support and analytics solutions to health systems and payers. Comparable as a broad healthcare AI/analytics incumbent with oncology CDS capabilities competing for health system IT budgets.
- Google Health: Large incumbent with AI healthcare initiatives spanning oncology screening, clinical decision support, and EHR-embedded tools. Comparable as a potential entrant in AI-driven cancer CDS that could leverage search-scale data and integration with major EHR vendors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
C the Signs social profiles
Digital presenceC the Signs compliance and trust
Trust signalCompliance4 records
C the Signs financial estimates
Financial estimateRevenue estimate
Valuation estimate
C the Signs leadership team
Management profileNumber of profiles
Profiles3 records
C the Signs funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
C the Signs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about C the Signs
What does C the Signs do?
C the Signs is an AI-powered clinical decision support platform that analyzes patient symptoms, demographics, risk factors, and electronic medical record data across 1,000+ validated evidence-based data points to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with NHS GP systems (EMIS, SystmOne, Vision) and is complemented by a patient-facing self-assessment service enabling direct triage into diagnostic pathways.
Is C the Signs a public or private company?
C the Signs is a private company. It is classified as venture growth investor backed and is currently operating.
When was C the Signs founded?
C the Signs was founded in 2017. It employs 11 to 50 people.
Where is C the Signs based?
C the Signs is headquartered in London, United Kingdom, in the Europe region.
How does C the Signs make money?
Two revenue lines are on record. NHS Commissioning Contracts are the primary driver. The others are health Innovation Partnerships.
Who are C the Signs's main competitors?
Direct peers on record are CancerIQ, Skin Analytics, Kheiron Medical Technologies, Cyted and Volpara Health. Emerging players are Lunit and PathAI. Broad incumbents are Tempus, Merative (formerly IBM Watson Health) and Google Health.
Does C the Signs have an API?
No public API is recorded for C the Signs.
What industry is C the Signs in?
C the Signs's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics, with a secondary code of HLACAEAF, Patient Intake, Digital Registration & eForms. Its NAICS code is 541512 and its SIC code is 8011.